BID, BAK, and BAD were not significantly enriched is the screening process (10 532nd, 1910th and 15 095th, respectively), perhaps suggesting a slightly lesser role of these genes with regard to imatinib resistance in CML. This evidence concerns the gene BID and chronic myelogenous leukemia, BCR-ABL1 positive.